Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib

Sa Rang Kim, Alexandra Charos, William Damsky, Peter Heald, Michael Girardi, Brett King

JAAD Case Reports · 2018 · 75 citations · 4 references

DOIFull text

Open access

Concepts

Abstract

Morphea is a fibrosing skin disease with a spectrum of presentations ranging from localized indurated plaques to circumferential involvement of limbs that impairs mobility.1 Eosinophilic fasciitis (EF) is often considered a severe form of morphea.1 Treatment of severe sclerosing diseases, such as generalized deep morphea (GDM) and EF, can be challenging. Methotrexate and prednisone are therapeutic mainstays but are not effective in all cases.1 A recent retrospective study showed that ruxolitinib, a Janus kinase (JAK)1/2 inhibitor, was effective in treating sclerodermatous cutaneous graft-versus-host disease.

References

4